PP
JSPR icon

Paloma Partners’s Jasper Therapeutics JSPR Stock Holding History

Paloma Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,014
Closed -$80K – 2006
2021
Q4 		$80K Buy
+1,014
New +$94.9K ﹤0.01% 1798

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's JSPR Position: Q1 2022 in Review

Paloma Partners sold out of Jasper Therapeutics (JSPR) in Q1 2022, closing a stake of 1,014 shares — an estimated $80K sold.

Paloma Partners first reported a position in JSPR in Q4 2021 and held it in 1 quarter. The position peaked at $80K in Q4 2021. 24 funds tracked by Wall St. Rank hold JSPR as of Q1 2022.

  • Paloma Partners reported no remaining Jasper Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Paloma Partners sold 1,014 Jasper Therapeutics shares in Q1 2022, an estimated $80K.
  • Paloma Partners first reported a position in Jasper Therapeutics in Q4 2021 and held it in 1 quarter.
  • Paloma Partners's Jasper Therapeutics position peaked at $80K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.